Methylphenidate Treatment of Cancer-Related Fatigue

Launched by MEDICE ARZNEIMITTEL PÜTTER GMBH & CO KG · Sep 24, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • history of Cancer
• • MFI \>40
• • Karnofsky Index \>=70
• • outpatient
• • patient are able to give informed consent
• Exclusion Criteria:
• • treatment with psychostimulants in the past two weeks before screening
• • active tumor disease
• • depression (HADS \>10)
• • cachexia (BMI \<18kg/m2)
• • clinically relevant kidney disorders
• • clinically relevant liver disorder
• • pathological ECG-finding
• • high blood pressure
• • occlusive arterial disease
• • angina pectoris
• • cardiac arrhythmias
• • CHD
• • post heart-attack status
• • post stroke status
• • known elevated intra-ocular pressure
• • known enlarged prostates
• • latent and manifest hyperthyreosis
• • alcohol, medication or drug dependency in the past six months or manifest drug abuse
• • participation in a clinical study within the past 30 days
• • participation in this study at an earlier point in time
• • simultaneous participation in another clinical trial
• • women of child-bearing age without adequate contraception (contraceptives, intrauterine device , no sexual intercourse)
• • pregnancy (positive pregnancy test) or lactation period